Patents by Inventor Weimin RUAN

Weimin RUAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Drug carrier, brain-targeting nanodrug based on CRISPR gene editing technology and preparation method and use thereof
    Patent number: 12161700
    Abstract: The present disclosure provides a drug carrier, a brain-targeting nanodrug based on CRISPR gene editing technology and a preparation method and use thereof. The nanodrug contains nanoparticles prepared by coupling Cas9/sgRNA and drug carriers. The drug carrier includes a polymer mPEG-P (GPMA, FPMA) and a polymer Ang-PEG-PGPMA, wherein a structural formula of the mPEG-P (GPMA, FPMA) is: a structural formula of the polymer Ang-PEG-PGPMA is: where n is 35-45, x1 is 15-20, y is 2-4, m is 75-85, and x2=x1. The guanidino group of the drug carrier can be combined with the ribonucleoprotein complex by electrostatic action, salt bridge formation, or hydrogen bonding action. Also provided are methods of suppressing and treating tumors at a gene level using the drug carrier to transport the therapeutic drug to the lesion site.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: December 10, 2024
    Assignee: Henan University
    Inventors: Weimin Ruan, Mingzhu Jiao, Bingyang Shi, Meng Zheng
  • Drug Carrier, Brain-targeting Nanodrug Based on CRISPR Gene Editing Technology and Preparation Method and Use thereof
    Publication number: 20210299228
    Abstract: The present disclosure provides a drug carrier, a brain-targeting nanodrug based on CRISPR gene editing technology and a preparation method and use thereof. The nanodrug contains nanoparticles prepared by coupling Cas9/sgRNA and drug carriers. The drug carrier includes a polymer mPEG-P (GPMA, FPMA) and a polymer Ang-PEG-PGPMA, wherein a structural formula of the mPEG-P (GPMA, FPMA) is: a structural formula of the polymer Ang-PEG-PGPMA is: where n is 35-45, x1 is 15-20, y is 2-4, m is 75-85, and x2=x1. The guanidino group of the drug carrier can be combined with the ribonucleoprotein complex by electrostatic action, salt bridge formation, or hydrogen bonding action. Also provided are methods of suppressing and treating tumors at a gene level using the drug carrier to transport the therapeutic drug to the lesion site.
    Type: Application
    Filed: December 4, 2020
    Publication date: September 30, 2021
    Inventors: Weimin RUAN, Mingzhu JIAO, Bingyang SHI, Meng ZHENG